KEY TAKEAWAYS
- The study aimed to validate CSF proteomic profiling and develop a panel for accurate PCNSL diagnosis.
- The study suggested a CSF-based proteomic panel could improve PCNSL diagnosis and differentiation, enhancing patient outcomes.
Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin’s lymphoma affecting the brain, eyes, cerebrospinal fluid (CSF), and spinal cord. Diagnosing PCNSL is challenging as imaging studies often resemble those of other brain tumors, and stereotactic brain biopsy is invasive and not always feasible.
Jingjing Ma and the team aimed to validate prior CSF proteomic profiling and create a CSF-based panel for accurate PCNSL diagnosis.
The study collected CSF samples from 30 patients with PCNSL, 30 with other brain tumors, and 31 tumor-free or benign controls. Liquid chromatography-tandem mass spectrometry targeted proteomics analysis was used to develop CSF-based proteomic panels.
The study’s final proteomic panels for diagnosing PCNSL achieved an area under the curve (AUC) of 0.873 (95% CI: 0.723-0.948) for distinguishing PCNSL from tumor-free controls and 0.937 (95% CI: 0.807-0.985) for differentiating it from other brain tumors.
Pathway analysis revealed that the diagnostic panel features were significantly enriched in pathways related to extracellular matrix-receptor interaction, focal adhesion, and PI3K-Akt signaling. In contrast, differentiation panel features were significantly enriched in pathways associated with prion disease, mineral absorption, and HIF-1 signaling.
The study suggests that a CSF-based proteomic panel can accurately diagnose and differentiate PCNSL, potentially overcoming current diagnostic challenges and improving patient outcomes.
This study is part of a research project (SHDC12020112) that was funded by Shanghai Shenkang Clinical Innovation Project. This study was also funded by Shanghai Municipal Health Commission Health Industry Clinical Research Project.
Source: https://pubmed.ncbi.nlm.nih.gov/39144147/
Ma J, Lin Z, Zhang Y, et al. (2024). “Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors.” Front Immunol. 2024;15:1343109. Published 2024 Aug 1. doi:10.3389/fimmu.2024.1343109
